CytomX Therapeutics Inc
NASDAQ:CTMX
Intrinsic Value
CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. [ Read More ]
The intrinsic value of one CTMX stock under the Base Case scenario is 3.09 USD. Compared to the current market price of 1.68 USD, CytomX Therapeutics Inc is Undervalued by 46%.
Valuation Backtest
CytomX Therapeutics Inc
Run backtest to discover the historical profit from buying and selling CTMX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
CytomX Therapeutics Inc
Current Assets | 182.9m |
Cash & Short-Term Investments | 174.5m |
Receivables | 3.4m |
Other Current Assets | 5m |
Non-Current Assets | 18.9m |
PP&E | 16.2m |
Intangibles | 1.7m |
Other Non-Current Assets | 1m |
Current Liabilities | 155.9m |
Accounts Payable | 1.5m |
Accrued Liabilities | 22.2m |
Other Current Liabilities | 132.3m |
Non-Current Liabilities | 93.3m |
Other Non-Current Liabilities | 93.3m |
Earnings Waterfall
CytomX Therapeutics Inc
Revenue
|
101.2m
USD
|
Operating Expenses
|
-107.7m
USD
|
Operating Income
|
-6.5m
USD
|
Other Expenses
|
5.9m
USD
|
Net Income
|
-569k
USD
|
Free Cash Flow Analysis
CytomX Therapeutics Inc
What is Free Cash Flow?
CTMX Profitability Score
Profitability Due Diligence
CytomX Therapeutics Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
Score
CytomX Therapeutics Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
CTMX Solvency Score
Solvency Due Diligence
CytomX Therapeutics Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Score
CytomX Therapeutics Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CTMX Price Targets Summary
CytomX Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for CTMX is 2.96 USD with a low forecast of 2.27 USD and a high forecast of 3.68 USD.
Ownership
CTMX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CTMX Price
CytomX Therapeutics Inc
Average Annual Return | -33.23% |
Standard Deviation of Annual Returns | 22.19% |
Max Drawdown | -93% |
Market Capitalization | 113.1m USD |
Shares Outstanding | 67 731 800 |
Percentage of Shares Shorted | 4.95% |
CTMX News
Last Important Events
CytomX Therapeutics Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
CytomX Therapeutics Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. The company is headquartered in South San Francisco, California and currently employs 174 full-time employees. The company went IPO on 2015-10-08. The firm is developing a class of investigational conditionally activated therapeutics, based on its Probody technology platform, for the treatment of cancer. Its Probody technology platform is designed to enable conditional activation of antibody-based drugs in the tumor microenvironment while minimizing drug activity in healthy tissues and in circulation. The company has utilized its multi-modality Probody platform to build a pipeline of therapeutics that encompasses six product candidates, four of which are in multiple Phase II clinical studies in nine cancer indications. The company includes the conditionally activated antibody-drug conjugates (ADCs) praluzatamab ravtansine (CX-2009, targeting CD166) and CX-2029 (targeting CD71), and the Probody immune CPIs pacmilimab (CX-072, targeting PD-L1) and BMS-986249 (targeting CTLA-4).
Contact
IPO
Employees
Officers
The intrinsic value of one CTMX stock under the Base Case scenario is 3.09 USD.
Compared to the current market price of 1.68 USD, CytomX Therapeutics Inc is Undervalued by 46%.